ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Mammographic breast density response to aromatase inhibition.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.The Cochrane database of systematic reviews · 2021Pooled it
- Relationship Between Breast Density and Selective Estrogen-Receptor Modulators, Aromatase Inhibitors, Physical Activity, and Diet: A Systematic Review.Integrative cancer therapies · 2016Pooled it
- Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812.JNCI cancer spectrum · 2024Trial
- Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.Breast cancer research : BCR · 2019Trial
- Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.Cancer prevention research (Philadelphia, Pa.) · 2016Trial
- Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.British journal of cancer · 2013Trial
- Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.Breast cancer research and treatment · 2022Article
- Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.Breast cancer research and treatment · 2021Article
- Biological Mechanisms and Therapeutic Opportunities in Mammographic Density and Breast Cancer Risk.Cancers · 2021Review
- Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.Breast cancer research and treatment · 2019Review
- The Potential for Mammographic Breast Density Change as a Biosensor of Adjuvant Tamoxifen Therapy Adherence and Response.JNCI cancer spectrum · 2018Article
- Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction.Archives of plastic surgery · 2018Article
- Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- Qualitative Versus Quantitative Mammographic Breast Density Assessment: Applications for the US and Abroad.Diagnostics (Basel, Switzerland) · 2017Review
- Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Suitable trial designs and cohorts for preventive breast cancer agents.Nature reviews. Clinical oncology · 2013Review
- Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy.Cancer control : journal of the Moffitt Cancer CenterArticle
- Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironmentOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
purposeMammographic breast density (MBD) is decreased by tamoxifen, but the effect of aromatase inhibitors is less clear. EXPERIMENTAL
designWe enrolled early-stage postmenopausal patients with breast cancer initiating adjuvant aromatase inhibitor therapy and ascertained mammograms before and at an average 10 months of aromatase inhibitor therapy. We matched cases to healthy postmenopausal women (controls) from a large mammography screening cohort on age, baseline body mass index, baseline MBD, and interval between mammograms. We estimated change in MBD using a computer-assisted thresholding program (Cumulus) and compared differences between cases and matched controls.
resultsIn predominantly White women (96%), we found 14% of the 387 eligible cases had a MBD reduction of at least 5% after an average of 10 months of aromatase inhibitor therapy. MBD reductions were associated with higher baseline MBD, aromatase inhibitor use for more than 12 months, and prior postmenopausal hormone use. Comparing each case with her matched control, there was no evidence of an association of change in MBD with aromatase inhibitor therapy [median case-control difference among 369 pairs was -0.1% (10th and 90th percentile: -5.9%, 5.2%) P = 0.51]. Case-control differences were similar by type of aromatase inhibitor (P's 0.41 and 0.56); prior use of postmenopausal hormones (P = 0.85); baseline MBD (P = 0.55); and length of aromatase inhibitor therapy (P = 0.08).
conclusionsIn postmenopausal women treated with aromatase inhibitors, 14% of cases had a MBD reduction of more than 5%, but these decreases did not differ from matched controls. These data suggest that MBD is not a clinically useful biomarker for predicting the value of aromatase inhibitor therapy in White postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.